TICKERNERD
Menu
BEAMBEAMHealthcare · Biotechnology

BEAM Stock Forecast: Beam Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$28
+5.68% on the day

The 15 Wall Street analysts covering Beam Therapeutics, Inc. hold a median 12-month price target of $44 — +58.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 3 Nov 2026 — in the lower half.

Market cap
$2.7B
Ticker Nerd rank
40/ 100
Median analyst target
$44
Analysts covering
15
Revenue$490K−94.2% y/y
Operating income−$126.6M
Net income−$122.7M
Free cash flow−$68.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
+13.6%
YTD
+0.4%
1Y
+22.4%
From 52W high
−26.6%
From 52W low
+35.1%
$21
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BEAM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beam Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Quality
73
Value
64
Momentum
57
Accruals
31
Size
31
Volatility
30
Revisions
29
Issuance
19

Growth (98): Sales and profits are climbing, and climbing faster than before.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BEAM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BEAM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26BEAMHigh $80Median $44Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
13 Buy2 Hold0 Sell
Low $26Median $44High $80

The green dot is the last close — the median target sits +58.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Oct 2026Canaccord GenuityMaintainsBuy$78 → $79
28 Oct 2026WedbushMaintainsOutperform$65 → $28
15 Oct 2026HC Wainwright & Co.ReiteratesBuy—
15 Oct 2026HC Wainwright & Co.ReiteratesBuy$80
14 Oct 2026WedbushReiteratesOutperform—
14 Oct 2026WedbushReiteratesOutperform$65
9 Sept 2026WedbushReiteratesOutperform$65
9 Sept 2026WedbushReiteratesOutperform—
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$80
25 Aug 2026HC Wainwright & Co.ReiteratesBuy—
8 July 2026B of A SecuritiesReiteratesBuy$47
8 July 2026B of A SecuritiesReiteratesBuy—
7 July 2026HC Wainwright & Co.ReiteratesBuy—
7 July 2026HC Wainwright & Co.ReiteratesBuy$80
13 May 2026BernsteinMaintainsOutperform—
26 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026RBC CapitalMaintainsSector Perform—
25 Feb 2026WedbushMaintainsOutperform—
20 Feb 2026Canaccord GenuityInitiatesBuy—
21 Jan 2026BernsteinMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BEAM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BEAM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Beam Therapeutics, Inc. returned +22.4% against +12.9% for the S&P 500, dividends included.

BEAM vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Jan 26Apr 26Jul 26Oct 26BEAMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BEAM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
5
Fundamentals

Beam Therapeutics, Inc. (BEAM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−32.5×

Cheaper than 98% of US stocks

Price / sales
17.6×

Cheaper than 9% of US stocks

Price / book
2.5×

Cheaper than 36% of US stocks

EV / EBITDA
−4.7×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
−94.2%

Higher than 2% of US stocks

Earnings growth (YoY)
−94.2%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−25827.1%

Higher than 1% of US stocks

Net margin
−55.4%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−8.2%

Higher than 37% of US stocks

Return on assets
−17.0%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Beam Therapeutics, Inc. (BEAM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Beam Therapeutics, Inc. has a market value of $2.7B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $156.0M. The latest quarter shrank 94.2% year on year.

  • Net income over the same four quarters: −$85.4M, a −54.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.86.

  • Free cash flow in the twelve months to 30 June 2026: −$372.8M.

  • Shares outstanding: 103.3M.

  • Trailing P/E: −32.5×; forward P/E: −5.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Beam Therapeutics, Inc. employs 540 people — $289K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

BEAM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BEAMBeam Therapeutics, Inc.$2.7B40
RCUSArcus Biosciences, Inc.$2.7B50
MBXMBX Biosciences, Inc.$2.6B43
VRDNViridian Therapeutics, Inc.$2.8B62
NRIXNurix Therapeutics, Inc.$2.8B91
ADMAADMA Biologics, Inc.$2.5B56
IDYAIDEAYA Biosciences, Inc.$2.9B67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Beam Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BEAM news & analysis

Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting

GlobeNewsWire · 4 Nov 2026positive

Beam Therapeutics said it will present updated BEACON Phase 1/2 trial data for risto-cel in sickle cell disease at the ASH Annual Meeting on December 12–15, 2026. The company said initial patient-reported outcomes showed early and sustained improvements across several well-being and symptom measures, and that a U.S. BLA submission is expected as early as year-end 2026.

Why it matters — The presentation and stated regulatory timeline provide BEAM watchers with updates on clinical results and the development path for risto-cel.

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research · 3 Nov 2026negative

Beam Therapeutics reported a quarterly loss of $1.28 per share, compared with the Zacks Consensus Estimate of a $1.17 loss and a loss of $1.10 per share a year earlier. The headline also says the company missed revenue estimates, though the excerpt provides no revenue figures.

Why it matters — BEAM watchers may note that the reported per-share loss was larger than both the consensus estimate and the year-ago loss.

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

GlobeNewsWire · 3 Nov 2026positive

Beam Therapeutics reported third-quarter 2026 financial results and clinical progress across its base-editing portfolio. Updated BEAM-302 Phase 1/2 data presented at ERS showed durable increases in functional AAT and reductions in mutant Z-AAT; dosing in the global pivotal cohort is expected to be completed in the first half of 2027.

Why it matters — The update highlights clinical findings and a dosing timeline for BEAM-302, a program in Beam’s portfolio.

3 Promising Genomics Stocks to Add to Your Portfolio Now

Zacks Investment Research · 30 Oct 2026neutral

Zacks Investment Research highlights genomics and synthetic biology as areas transforming healthcare through precision medicine and gene editing, focusing on ILMN, QURE and TXG. The headline presents these as promising stocks to add to a portfolio.

Why it matters — The article reflects broader interest in genomics and gene editing, sectors relevant to a BEAM watcher, but does not mention Beam Therapeutics.

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Zacks Investment Research · 29 Oct 2026neutral

Beam Therapeutics shares rose 15.6% in the last session, on above-average trading volume. The excerpt says recent earnings estimate revisions may not lead to further near-term price gains.

Why it matters — BEAM watchers may note the sharp session move alongside the caution that estimate revisions may not sustain further near-term gains.

FAQ

Frequently asked questions about BEAM stock

What is the BEAM stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Beam Therapeutics, Inc. have a median 12-month price target of $44, with estimates ranging from $26 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BEAM stock a buy right now?

Of the 15 analysts covering Beam Therapeutics, Inc., 13 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beam Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BEAM?

As at 3 Nov 2026, Beam Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will BEAM stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +58.1% from the last close, and Ticker Nerd's factor model ranks Beam Therapeutics, Inc. 40 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BEAM stock forecast for 2030?

No analyst covering Beam Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $80 over the next 12 months.

How has BEAM stock performed over the past year?

Beam Therapeutics, Inc. returned +22.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Beam Therapeutics, Inc. do?

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform.

What is the latest news on BEAM?

The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting". Beam Therapeutics said it will present updated BEACON Phase 1/2 trial data for risto-cel in sickle cell disease at the ASH Annual Meeting on December 12–15, 2026. The company said initial patient-reported outcomes showed early and sustained improvements across several well-being and symptom measures, and that a U.S. BLA submission is expected as early as year-end 2026.

Company

About Beam Therapeutics, Inc.

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company works on therapies designed to make targeted, single-letter changes in DNA without creating double-strand breaks, supporting programs aimed at serious genetic and hematologic diseases. Its current pipeline includes research and clinical candidates across areas such as blood disorders, liver diseases, and other rare conditions. Beam Therapeutics also maintains integrated capabilities in gene editing, delivery, and internal manufacturing to support the development of its therapeutic candidates. Based in Cambridge, Massachusetts, Beam Therapeutics plays a role in the advanced genomics and gene-editing market, where precision medicine approaches are being applied to address diseases with limited treatment options.

CEO Mr. John M. Evans M.B.A. · 540 employees · United States · https://beamtx.com